Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
نویسندگان
- L. Marije Hofstra
- Nicolas Sauvageot
- Jan Albert
- Ivailo Alexiev
- Federico Garcia
- Daniel Struck
- David A. M. C. Van de Vijver
- Birgitta Åsjö
- Danail Beshkov
- Suzie Coughlan
- Diane Descamps
- Algirdas Griskevicius
- Osamah Hamouda
- Andrzej Horban
- Marjo Van Kasteren
- Tatjana Kolupajeva
- Leondios G. Kostrikis
- Kirsi Liitsola
- Marek Linka
- Orna Mor
- Claus Nielsen
- Dan Otelea
- Dimitrios Paraskevis
- Roger Paredes
- Mario Poljak
- Elisabeth Puchhammer-Stöckl
- Anders Sönnerborg
- Danica Staneková
- Maja Stanojevic
- Kristel Van Laethem
- Maurizio Zazzi
- Snjezana Zidovec Lepej
- Charles A. B. Boucher
- Jean-Claude Schmit
- Annemarie M. J. Wensing
- E. Puchhammer-Stockl
- M. Sarcletti
- B. Schmied
- M. Geit
- G. Balluch
- A.-M. Vandamme
- J. Vercauteren
- I. Derdelinckx
- A. Sasse
- M. Bogaert
- H. Ceunen
- A. De Roo
- S. De Wit
- F. Echahidi
- K. Fransen
- J.-C. Goffard
- P. Goubau
- E. Goudeseune
- J.-C. Yombi
- P. Lacor
- C. Liesnard
- M. Moutschen
- D. Pierard
- R. Rens
- Y. Schrooten
- D. Vaira
- L. P. R. Vandekerckhove
- A. Van den Heuvel
- B. Van Der Gucht
- M. Van Ranst
- E. Van Wijngaerden
- B. Vandercam
- M. Vekemans
- C. Verhofstede
- N. Clumeck
- K. Van Laethem
- D. Beshkov
- I. Alexiev
- S. Zidovec Lepej
- J. Begovac
- L. Kostrikis
- I. Demetriades
- I. Kousiappa
- V. Demetriou
- J. Hezka
- M. Linka
- M. Maly
- L. Machala
- C. Nielsen
- L. B. Jørgensen
- J. Gerstoft
- L. Mathiesen
- C. Pedersen
- H. Nielsen
- A. Laursen
- B. Kvinesdal
- K. Liitsola
- M. Ristola
- J. Suni
- J. Sutinen
- D. Descamps
- L. Assoumou
- G. Castor
- M. Grude
- P. Flandre
- A. Storto
- O. Hamouda
- C. Kücherer
- T. Berg
- P. Braun
- G. Poggensee
- M. Däumer
- J. Eberle
- H. Heiken
- R. Kaiser
- H. Knechten
- K. Korn
- H. Müller
- S. Neifer
- B. Schmidt
- H. Walter
- B. Gunsenheimer-Bartmeyer
- T. Harrer
- D. Paraskevis
- A. Hatzakis
- A. Zavitsanou
- A. Vassilakis
- M. Lazanas
- M. Chini
- A. Lioni
- V. Sakka
- S. Kourkounti
- V. Paparizos
- A. Antoniadou
- A. Papadopoulos
- G. Poulakou
- I. Katsarolis
- K. Protopapas
- G. Chryssos
- S. Drimis
- P. Gargalianos
- G. Xylomenos
- G. Lourida
- M. Psichogiou
- G. L. Daikos
- N. V. Sipsas
- A. Kontos
- M. N. Gamaletsou
- G. Koratzanis
- H. Sambatakou
- H. Mariolis
- A. Skoutelis
- V. Papastamopoulos
- O. Georgiou
- P. Panagopoulos
- E. Maltezos
- S. Coughlan
- C. De Gascun
- C. Byrne
- M. Duffy
- C. Bergin
- D. Reidy
- G. Farrell
- J. Lambert
- E. O'Connor
- A. Rochford
- J. Low
- P. Coakely
- S. O'Dea
- W. Hall
- O. Mor
- I. Levi
- D. Chemtob
- Z. Grossman
- M. Zazzi
- A. de Luca
- C. Balotta
- C. Riva
- C. Mussini
- I. Caramma
- A. Capetti
- M. C. Colombo
- C. Rossi
- F. Prati
- F. Tramuto
- F. Vitale
- M. Ciccozzi
- G. Angarano
- G. Rezza
- T. Kolupajeva
- O. Vasins
- A. Griskevicius
- V. Lipnickiene
- J. C. Schmit
- D. Struck
- N. Sauvageot
- R. Hemmer
- V. Arendt
- C. Michaux
- T. Staub
- C. Sequin-Devaux
- A. M. J. Wensing
- C. A. B. Boucher
- D. A. M. C. van de Vijver
- A. van Kessel
- P. H. M. van Bentum
- K. Brinkman
- B. J. Connell
- M. E. van der Ende
- I. M. Hoepelman
- M. van Kasteren
- M. Kuipers
- N. Langebeek
- C. Richter
- R. M. W. J. Santegoets
- L. Schrijnders-Gudde
- R. Schuurman
- B. J. M. van de Ven
- B. Åsjö
- A.-M. Bakken Kran
- V. Ormaasen
- P. Aavitsland
- A. Horban
- J. J. Stanczak
- G. P. Stanczak
- E. Firlag-Burkacka
- A. Wiercinska-Drapalo
- E. Jablonowska
- E. Maolepsza
- M. Leszczyszyn-Pynka
- W. Szata
- R. Camacho
- C. Palma
- F. Borges
- T. Paixão
- V. Duque
- F. Araújo
- D. Otelea
- S. Paraschiv
- A.M. Tudor
- R. Cernat
- C. Chiriac
- F. Dumitrescu
- L. J. Prisecariu
- M. Stanojevic
- Dj. Jevtovic
- D. Salemovic
- D. Stanekova
- M. Habekova
- Z. Chabadová
- T. Drobkova
- P. Bukovinova
- A. Shunnar
- P. Truska
- M. Poljak
- M. Lunar
- D. Babic
- J. Tomazic
- L. Vidmar
- T. Vovko
- P. Karner
- F. Garcia
- R. Paredes
- S. Monge
- S. Moreno
- J. del Amo
- V. Asensi
- J. L. Sirvent
- C. de Mendoza
- R. Delgado
- F. Gutiérrez
- J. Berenguer
- S. Garcia-Bujalance
- N. Stella
- I. de los Santos
- J. R. Blanco
- D. Dalmau
- M. Rivero
- F. Segura
- M. J. Pérez Elías
- M. Alvarez
- N. Chueca
- C. Rodríguez-Martín
- C. Vidal
- J. C. Palomares
- I. Viciana
- P. Viciana
- J. Cordoba
- A. Aguilera
- P. Domingo
- M.J. Galindo
- C. Miralles
- M. A. del Pozo
- E. Ribera
- J. A. Iribarren
- L. Ruiz
- J. de la Torre
- F. Vidal
- B. Clotet
- J. Albert
- A. Heidarian
- K. Aperia-Peipke
- M. Axelsson
- M. Mild
- A. Karlsson
- A. Sönnerborg
- A. Thalme
- L. Navér
- G. Bratt
- A. Blaxhult
- M. Gisslén
- B. Svennerholm
- I. Bergbrant
- P. Björkman
- C. Säll
- Å. Mellgren
- A. Lindholm
- N. Kuylenstierna
- R. Montelius
- F. Azimi
- B. Johansson
- M. Carlsson
- E. Johansson
- B. Ljungberg
- H. Ekvall
- A. Strand
- S. Mäkitalo
- S. Öberg
- P. Holmblad
- M. Höfer
- H. Holmberg
- P. Josefson
- U. Ryding
چکیده
BACKGROUND Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
منابع مشابه
Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa.
PURPOSE OF REVIEW This review provides an update of recent data on the development of HIV-1 drug resistance during treatment and its transmission in sub-Saharan Africa after the scale-up of antiretroviral therapy (ART). RECENT FINDINGS Evidence is accumulating of a rising prevalence of transmitted HIV drug resistance (TDR), predominantly associated with nonnucleoside reverse transcriptase inh...
متن کاملبررسی میزان فراوانی مقاومت دارویی در بیماران HIV/AIDS تحت درمان، مراجعهکننده به بیمارستان امامخمینی تهران از سال 87 لغایت 88: نامه به سردبیر
The combinations of antiretroviral (ARV) drugs have proven effective in controlling the progression of AIDS, but these benefits can be compromised by drug resistance. Thus, drug-resistance testing has become an important tool in the management of HIV-infected individuals.1 Drug resistance develops when mutations in the HIV virus proteins occur due to amino acid substitutions.2 Drug resistance t...
متن کاملSecond-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.
Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associate...
متن کاملEffect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.
BACKGROUND There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use. METHODS A stochastic simulation model of transmission of HIV, natural history and the effect of ART, was developed and used to predict the proportion of new infections with resistance according...
متن کاملInefficient vaginal transmission of tenofovir-resistant HIV-1.
Transmission of drug-resistant HIV has been postulated to be a threat to current first-line antiretroviral therapy (ART) regimens and the efficacy of several antiretroviral-based preexposure prophylaxis (PrEP) strategies being tested. Here we evaluated the effect of the common tenofovir (TFV) resistance mutation K65R on vaginal HIV transmission. Our results demonstrate that despite no overt los...
متن کاملStudy of HIV seroprevalence in Pulmonary Tuberculosis Patients with Special Reference to Multidrug Resistant Mycobacteria
This study was planned to determine HIV seroprevalence among pulmonary tuberculosis patients, to characterize the isolated mycobacteria into typical and atypical strains and to evaluate the drug resistant pattern of mycobacterial isolates. The study aims to correlate multidrug resistance (MDR) and HIV seropositivity status in pulmonary tuberculosis patients. During the year 1994-1997, 750 pulmo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 62 شماره
صفحات -
تاریخ انتشار 2016